Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | SPR | P35270 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | GABRP | O00591 | 1/20 | 0.56 |
| ▸ | GABRD | O14764 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.56 |
| ▸ | GABRE | P78334 | 1/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30228513 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1SPRSMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL30228556 | 0.98 | KDM4E (0.64) | KDM4EALDH1A1SPRSMN1; SMN2POLB | |
| SCHEMBL5240303 | 0.85 | KDM4E (0.63) | KDM4EALDH1A1SMN1; SMN2HSD17B10GABRP | |
| SCHEMBL30883973 | 0.84 | SRC (0.56) | KDM4EALDH1A1HSD17B10GABRPGABRD | |
| SCHEMBL15987388 | 0.84 | SRC (0.56) | KDM4EALDH1A1HSD17B10GABRPGABRD | |
| SCHEMBL2885250 | 0.84 | MEN1 (0.74) | KDM4EALDH1A1SMN1; SMN2HSD17B10CYP1A2 | |
| SCHEMBL27765520 | 0.84 | KDM4E (0.61) | KDM4EALDH1A1SMN1; SMN2GABRPGABRD | |
| SCHEMBL14829909 | 0.82 | ALDH1A1 (0.80) | KDM4EALDH1A1SMN1; SMN2POLBHSD17B10 | |
| SCHEMBL5235188 | 0.82 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2HSD17B10GABRP | |
| SCHEMBL25941522 | 0.82 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2HSD17B10GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4209492-A1 | COMPOUND FOR TREATING THROMBOTIC DISEASES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2023-07-12 | — | — | EP | disclosed |
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3124489-A1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | Fibrogen, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2016078-B1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2016-06-15 | — | — | EP | disclosed |
| CN-103497184-A | Pyrrolo-and thiazolo-pyridine compounds as HIF modulators | FIBROGEN INC | 2014-01-08 | — | — | CN | disclosed |
| US-7696223-B2 | [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) | FIBROGEN, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| CN-101460497-A | Pyrrolopyridine and thiazolopyridine compounds as HIF modulators | FIBROGEN INC (US) | 2009-06-17 | — | — | CN | disclosed |
| EP-2016078-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007115315-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115315-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1603914-B1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2007-01-17 | — | — | EP | disclosed |
| US-20060281786-A1 | Compounds having activity at 5ht2c receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2006-12-14 | — | — | US | disclosed |
| EP-1603914-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004081010-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| US-5189041-A | Gastrointestinal and nervous system disorders, cardiovascular disorders, analgesics | SYNTEX (U.S.A.) INC. (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0485962-A2 | New tricyclic compounds | SYNTEX (U.S.A.) INC. (US) | 1992-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | KDM4E 754/4885ALDH1A1 1047/4885SPR 496/4885 |
| US-20060281786-A1 | Compounds having activity at 5ht2c receptor and uses thereof | HTR2C, HTR4, HTR3C | KDM4E 3146/4885ALDH1A1 1159/4885SPR 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.